Skip to main content
Terug
Watch Compare

Immuneering Corp

Datakwaliteit: 83%
IMRX
NASDAQ Manufacturing Chemicals
€ 5,52
▼ € 0,14 (-2,47%)
Marktkapitalisatie: 358,82 M
Prijs
€ 5,55
Marktkapitalisatie
358,82 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Negative free cash flow of -45,49 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-43,61%
Boven sectorgemiddelde (-54,44%)
ROIC-35,52%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio24,00
Interest CoverageN/A

Waardering

PE (TTM|NTM)
-6,40 | -4,08
Onder sectorgemiddelde (-1,49)
P/B Ratio1,57
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1385 peers)
Metriek Aandeel Sector Mediaan
P/E -6,4 -1,5
P/B 1,6 1,6
ROE % -43,6 -54,4
Net Margin % — -41,5
Rev Growth 5Y % — 1,9
D/E — 0,3

Koersdoel Analisten

6 analisten
Buy
Huidig
€ 5,52
+208.0%
Koersdoel
€ 17,00
€ 11,00
€ 14,50
€ 30,00
Vooruitzicht
Forward K/W -4,08
Forward WPA -€ 1,35
Omzet Sch. 19,20 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 -€ 1,35
-€ 1,73 – -€ 0,67
 19,20 M 6
FY2026 -€ 1,19
-€ 1,37 – -€ 0,99
 0,0 6

Winstverassingen

Laatste 4 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q42025 -€ 0,31 -€ 0,18 +42,3%
Q32025 -€ 0,39 -€ 0,38 +2,2%
Q22025 -€ 0,40 -€ 0,40 -0,5%
Q12025 -€ 0,59 -€ 0,42 +28,2%

ETFs Holding This Stock

CNCR CNCR
1,01% weight
BRUSX BRUSX
0,44% weight
BRSIX BRSIX
0,08% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -56,02 M
ROE -43,61% ROA -39,86%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -45,49 M
ROIC -35,52% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 24,00
Interest Coverage N/A Asset Turnover N/A
Working Capital 219,56 M Tangible Book Value 220,96 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -6,40 Forward P/E -4,08
P/B Ratio 1,57 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 18,69 Fwd Earnings Yield N/A
FCF Yield -12,68%
Market Cap 358,82 M Enterprise Value 131,26 M
Per Share
EPS (Diluted TTM) -1,27 Revenue / Share N/A
FCF / Share -0,70 OCF / Share -0,70
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 81,19%
SBC-Adj. FCF -51,80 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — 0,0 316.952,0 2,08 M
Net Income -56,02 M -61,04 M -53,47 M -50,51 M -33,54 M
EPS (Diluted) -1,27 -2,04 -1,88 -1,90 -2,46
Gross Profit — — 0,0 158.830,0 926.888,0
Operating Income -59,38 M -64,07 M -58,41 M -51,74 M -33,89 M
EBITDA — — — — —
R&D Expenses 42,05 M 47,96 M 41,62 M 36,27 M 26,54 M
SG&A Expenses — — — — —
D&A 324.517,0 355.807,0 — — —
Interest Expense — — — — —
Income Tax 0,0 — — -307.485,0 -307.485,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 231,99 M 52,71 M 102,58 M 122,37 M 166,70 M
Total Liabilities 13,50 M 11,33 M 12,01 M 12,52 M 10,72 M
Shareholders' Equity 218,48 M 41,39 M 90,58 M 109,85 M 155,98 M
Total Debt — — — — —
Cash & Equivalents 128,65 M 36,14 M 59,41 M 72,64 M 74,89 M
Current Assets 176,25 M 39,59 M 89,08 M 108,75 M 152,33 M
Current Liabilities 10,07 M 7,50 M 7,85 M 8,05 M 5,63 M